Sight Sciences, Inc.
Business
Sight Sciences develops transformative interventional ophthalmic technologies for two major eye diseases: glaucoma and dry eye disease. The company offers OMNI Surgical System and SION Surgical Instrument for microinvasive glaucoma surgery (MIGS) procedures, and TearCare System for meibomian gland disease treatment. Sight Sciences sells primarily in the United States through dedicated sales teams to ambulatory surgery centers, hospital outpatient departments, and eye care practices, with expanding international operations in the United Kingdom and Germany.
Summary from 10-K filed 2026-03-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 77 | 80 | 81 | 71 | 49 | |
| Cost of goods sold | 11 | 12 | 12 | 12 | 9 | |
| Gross profit | 67 | 68 | 69 | 59 | 40 | |
| Research and development | 15 | 18 | 18 | 23 | 16 | |
| Selling, general and administrative | 89 | 101 | 109 | 120 | 76 | |
| Total operating expenses | 104 | 119 | 126 | 143 | 92 | |
| Loss from operations | −37 | −51 | −57 | −84 | −51 | |
| Investment income | 4 | 6 | 7 | — | — | |
| Interest expense | −5 | −5 | −5 | −4 | −4 | |
| Loss on debt extinguishment | 0 | −2 | 0 | — | — | |
| Other expense, net | −148,000 | −32,000 | −44,000 | 2 | −7 | |
| Loss before income taxes | −38 | −51 | −55 | −86 | −63 | |
| Provision for income taxes | 10,000 | 236,000 | 110,000 | 47,000 | 188,000 | |
| Net loss and comprehensive loss | −38 | −52 | −56 | −86 | −63 | |
| Net loss per share attributable to common stockholders-basic | −0.74 | −1.03 | −1.14 | −1.8 | −2.36 | |
| Net loss per share attributable to common stockholders-diluted | −0.74 | −1.03 | −1.14 | −1.8 | −2.36 | |
| Weighted-average shares of common stock outstanding-basic | 52 | 50 | 49 | 48 | 27 | |
| Weighted-average shares of common stock outstanding-diluted | 52 | 50 | 49 | 48 | 27 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 92 | 120 | 138 | 185 | 261 | |
| Accounts receivable, net of allowance for credit losses of $234 and $689 at December 31, 2025 and 2024, respectively | 10 | 11 | 14 | 15 | 9 | |
| Inventory, net | 8 | 6 | 8 | 6 | 3 | |
| Prepaid expenses and other current assets | 3 | 2 | 3 | 3 | 4 | |
| Total current assets | 113 | 140 | 163 | 210 | 277 | |
| Property and equipment, net | 2 | 2 | 2 | 2 | 1 | |
| Operating lease right-of-use assets | 438,000 | 935,000 | 1 | 2 | 1 | |
| Other noncurrent assets | 518,000 | 550,000 | 682,000 | 211,000 | 202,000 | |
| Total assets | 115 | 143 | 167 | 213 | 280 | |
| Accounts payable | 1 | 2 | 2 | 3 | 3 | |
| Accrued compensation | 6 | 10 | 5 | 7 | 6 | |
| Accrued and other current liabilities | 4 | 4 | 4 | 8 | 4 | |
| Total current liabilities | 11 | 15 | 12 | 18 | 14 | |
| Long-term debt, net of current portion | 40 | 39 | 32 | 33 | 33 | |
| Other noncurrent liabilities | 31,000 | 492,000 | 2 | 2 | 2 | |
| Total liabilities | 51 | 55 | 46 | 53 | 48 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively | 0 | 0 | 0 | 0 | 0 | |
| Common stock, par value $0.001 per share; 200,000,000 shares authorized; 53,493,711 and 50,937,999 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 54,000 | 51,000 | 49,000 | 48,000 | 48,000 | |
| Additional paid-in-capital | 449 | 434 | 415 | 399 | 385 | |
| Accumulated deficit | −385 | −346 | −295 | −239 | −153 | |
| Total stockholders' equity | 64 | 88 | 120 | 160 | 232 | |
| Total liabilities and stockholders' equity | 115 | 143 | 167 | 213 | 280 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −38 | −52 | −56 | −86 | −63 | |
| Depreciation and amortization | 487,000 | 712,000 | 614,000 | — | — | |
| Accretion of debt discount and debt issuance costs | 944,000 | 753,000 | 614,000 | 657,000 | 701,000 | |
| Stock-based compensation expense | 13 | 17 | 15 | 13 | 5 | |
| Allowance for credit losses | 129,000 | −42,000 | 198,000 | 402,000 | 348,000 | |
| Provision (benefit) for excess and obsolete inventories | 0 | −106,000 | 418,000 | 614,000 | 436,000 | |
| Noncash operating lease cost | 498,000 | 646,000 | 1 | 542,000 | 569,000 | |
| Loss on disposal of property and equipment | 4,000 | 23,000 | 66,000 | 85,000 | 115,000 | |
| Noncash loss on debt extinguishment | 0 | 1 | 0 | — | — | |
| Change in fair value of common stock warrants | 11,000 | 60,000 | 0 | 0 | 7 | |
| Accounts receivable | 912,000 | 4 | 661,000 | −7 | −4 | |
| Inventory | −1 | 2 | −2 | −3 | −1 | |
| Prepaid expenses and other current assets | −686,000 | 299,000 | 812,000 | 751,000 | −3 | |
| Other noncurrent assets | −150,000 | −51,000 | −470,000 | −10,000 | 185,000 | |
| Accounts payable | −348,000 | 336,000 | −883,000 | −694,000 | 1 | |
| Accrued compensation | −4 | 5 | −3 | 1 | 2 | |
| Accrued and other current liabilities | −1 | −347,000 | −5 | 3 | 342,000 | |
| Other noncurrent liabilities | 0 | −2 | 330,000 | 353,000 | 72,000 | |
| Net cash used in operating activities | −30 | −22 | −47 | −76 | −53 | |
| Purchases of property and equipment | −224,000 | −385,000 | −791,000 | −970,000 | −813,000 | |
| Net cash used in investing activities | −224,000 | −385,000 | −791,000 | −970,000 | −813,000 | |
| Net proceeds from Hercules Loan Agreement | 0 | 40 | 0 | — | — | |
| Repayment of MidCap Loan Agreement | 0 | −35 | 0 | — | — | |
| Debt issuance costs | 0 | −238,000 | 0 | — | 0 | |
| Proceeds from exercise of common stock options | 1 | 255,000 | 395,000 | 576,000 | 355,000 | |
| Taxes paid on net settlement of restricted stock units | −58,000 | −23,000 | −224,000 | 0 | — | |
| Proceeds from employee stock purchase plan purchases | 758,000 | 819,000 | 933,000 | 672,000 | 0 | |
| Net cash provided by financing activities | 2 | 5 | 1 | 1 | 253 | |
| Net change in cash and cash equivalents | −28 | −18 | −47 | −76 | 199 | |
| Cash paid for interest | 4 | 4 | 4 | 3 | 3 | |
| Acquisition of property and equipment included in accounts payable and accrued liabilities | 114,000 | 169,000 | 60,000 | 103,000 | 162,000 | |
| Common stock warrants issued upon execution of Hercules Loan Agreement | 0 | 687,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Sight Sciences, Inc.'s CIK number?
Sight Sciences, Inc.'s SEC CIK number is 0001531177 (1531177). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Sight Sciences, Inc.'s SEC filings?
All of Sight Sciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Sight Sciences, Inc. last report earnings?
Sight Sciences, Inc. (SGHT) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-208959). This is Sight Sciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Sight Sciences, Inc.'s most recent earnings 8-K?
Sight Sciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001193125-26-208959. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Sight Sciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →